Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 and Sintilimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT04945421Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jul 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI310 in nasopharyngeal carcinoma (NPC), sponsored by Innovent Biologics. Primary endpoint: Objective Response Rate up to 2 years. Started Jul 2021; status: completed.
02
Drugs
IBI310
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04945421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945421.